| Sex at birth (n: 139) | |
| Men, n (%) | 47 (34) |
| Women, n (%) | 92 (66) |
| Age (years) Average (Range) | |
| Study population | 44 (17 - 77) |
| Men | 46 (17 - 70) |
| Women | 43 (18 - 77) |
| Therapeutic status n (%) | |
| Naive | 36 (24) |
| On ARV treatment | 103 (76) |
| Viral load (Log10 copies/mL) Median (Interval) | 4.8 (3 - 8) |
| Duration of treatment (years) Mean (Interval) | 5 (1 - 19) |
| Therapeutic lines | |
| ARV-naive subjects | 36 (26) |
| ARV regimen | 103 (74) |
| TDF-3TC-DTG/AZT-3TC-DTG /TDF-3TC-DTG-DRV/r | 50 (48) |
| TDF-3TC-EFV | 15 (15) |
| TDF-3TC-LPV/r | 3 (3) |
| TDF-3TC-ATV/r | 3 (3) |
| TDF-3TC-DRV/r | 1 (1) |
| TDF-3TC-DRV-RAL/r | 1 (1) |
| AZT-3TC-LPV/r | 11 (11) |
| AZT-3TC-ATV/r | 9 (9) |
| AZT-3TC-EFV | 1 (1) |
| ABC-3TC-ATV/r | 4 (4) |
| ABC-3TC-EFV | 2 (2) |
| ABC-3TC-LPV/r | 3 (3) |